Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: Relation to blood-brain barrier injury

Neurology

Volumn 46, Issue 6, 1996, Pages 1626-1632

  Rosenberg, G A ^a   Dencoff, J E ^b   Correa Jr , N ^b   Reiners, M ^b   Ford, C C ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; GELATINASE; METALLOPROTEINASE; METHYLPREDNISOLONE; TISSUE INHIBITOR OF METALLOPROTEINASE; UROKINASE;

ARTICLE; BLOOD BRAIN BARRIER; CAPILLARY PERMEABILITY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DRUG MECHANISM; ENZYME RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; STEROID THERAPY;

EID: 0029889674     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.6.1626     Document Type: Article

References (45)

1. Dawson JW. The histology of disseminated sclerosis. Trans R Soc Edin 1916;50:517-525.
2. Putnam TJ, Adler A. Vascular architecture of the lesions of multiple sclerosis. Arch Neurol Psychiatry 1937;38:1-15.
3. Fog T. On the vessel-plaque relationships in the brain in multiple sclerosis. Acta Neurol Scand Suppl 1964;10:9-15.
4. Adams CW, Abdulla YH, Torres EM, Poston RN. Periventricular lesions in multiple sclerosis: their perivenous origin and relationship to granular ependymitis. Neuropathol Appl Neurobiol 1987;13:141-152.
5. Sears ES, Tindall RSA, Zarnow H. Active multiple sclerosis. Enhanced computerized tomographic imaging of lesions and the effect of corticosteroids. Arch Neurol 1978;35:426-434.
6. Grossman RI, Gonzalez-Scarano F, Atlas SW, Galetta S, Silberberg DH. Multiple sclerosis: gadolinium enhancement in MR imaging. Radiology 1986;161:721-725.
7. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;116:1077-1094.
8. Rosenberg GA, Kornfeld M, Estrada E, Kelley RO, Liotta LA, Stetler-Stevenson WG. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992; 576:203-207.
9. Rosenberg GA, Dencoff JE, McGuire PG, Liotta LA, Stetler-Stevenson WG. Injury-induced 92-kDa gelatinase and urokinase expression in rat brain. Lab Invest 1994;71:417-422.
10. Rinne UK, Riekkinen P. Esterase, peptidase and proteinase activities of human cerebrospinal fluid in multiple sclerosis. Acta Neurol Scand 1968;44:156-167.
11. Hallpike JF, Adams CW. Proteolysis and myelin breakdown: a review of recent histochemical and biochemical studies. Histochem J 1969;1:559-578.
12. Cuzner ML, Davison AN, Rudge P. Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis. Ann Neurol 1978;4:337-344.
13. Inuzuka T, Sato S, Baba H, Miyatake T. Neutral protease in cerebrospinal fluid from patients with multiple sclerosis and other neurological diseases. Acta Neurol Scand 1987;76:18-23.
14. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41:29-34.
15. Troiano R, Hafstein M, Ruderman M, Dowling P, Cook S. Effect of high-dose intravenous steroid administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis. Ann Neurol 1984;15:257-263.
16. Burnham JA, Wright RR, Dreisbach J, Murray RS. The effect of high-dose steroids on MRI gadolinium enhancement in acute demyelinating lesions. Neurology 1991;41:1349-1354.
17. Barkhof F, Frequin STFM, Hommes OR, et al. A correlative triad of gadolinium-DTPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. Neurology 1992;42:63-67.
18. Jonat C, Rahmsdorf HJ, Park KK, et al. Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 1990;62:1189-1204.
19. Shapiro SD, Campbell EJ, Kobayashi DK, Welgus HG. Dexamethasone selectively modulates basal and lipopolysaccharide-induced metalloproteinase and tissue inhibitor of metalloproteinase production by human alveolar macrophages. J Immunol 1991;146:2724-2729.
20. Sato H, Seiki M. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993;8:395-405.
21. Heussen C, Dowdle EB. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. Anal Biochem 1980; 102:196-202.
22. Kodama S, Kishi JI, Obata K, Iwata KI, Hayakawa T. Monoclonal antibodies to bovine collagenase inhibitor. Coll Rel Res 1987;7:341-350.
23. r 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993;53:140-146.
24. Ramos-DeSimone N, Moll UM, Quigley JP, French DL. Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody. Hybridoma 1993;12:349-363.
25. Leco KJ, Khokha R, Pavloff N, Hawkes SP, Edwards DR. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994;269: 9352-9360.
26. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991;5:2145-2154.
27. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-68.
28. Cawston TE, Galloway WA, Mercer E, Murphy G, Reynolds JJ. Purification of rabbit bone inhibitor of collagenase. Biochem J 1981;195:159-165.
29. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 1990;265:13933-13938.
30. Murrell GAC, Jang D, Williams RJ. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995;206:15-21.
31. Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M. Prolonged activation of jun and collagenase genes by tumour necrosis factor-α. Nature 1989;337:661-663.
32. Rosenberg GA, Estrada EY, Dencoff JE, Stetler-Stevenson WG. TNF-α-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 1995;703:151-155.
33. Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA. Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 1990;40:1735-1739.
34. Sharief MK, Hentges R. Association between tumor necrosis factor-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-472.
35. Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994;94:2177-2182.
36. Herron GS, Werb Z, Dwyer K, Banda MJ. Secretion of metalloproteinases by stimulated capillary endothelial cells. I. Production of procollagenase and prostromelysin exceeds expression of proteolytic activity. J Biol Chem 1986;261:2810-2813.
37. Apodaca G, Rutka JT, Bouhana K, et al. Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 1990;50:2322-2329.
38. Colton CA, Keri JE, Chen WT, Monsky WL. Protease production by cultured microglia: substrate gel analysis and immobilized matrix degradation. J Neurosci Res 1993;35:297-304.
39. 2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-2168.
40. Reich R, Thompson EW, Iwamoto Y, et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988;48:3307-3312.
41. Teale DM, Khidair IA, Potter CW, Rees RC. Modulation of type IV collagenase and plasminogen activator in a hamster fibrosarcoma by basement membrane components and lung fibroblasts. Br J Cancer 1988;57:475-480.
42. He CS, Wilhelm SM, Pentland AP, et al. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989;86:2632-2636.
43. Reith A, Rucklidge GJ. Invasion of brain tissue by primary glioma: evidence for the involvement of urokinase-type plasminogen activator as an activator of type IV collagenase. Biochem Biophys Res Commun 1992;186:348-354.
44. Cammer W, Bloom BR, Norton WT, Gordon S. Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: a possible mechanism of inflammatory demyelination. Proc Natl Acad Sci USA 1978;75:1554-1558.
45. Pavloff N, Staskus PW, Kishnani NS, Hawkes SP. A new inhibitor of metalloproteinases from chicken: ChIMP-3. A third member of the TIMP family. J Biol Chem 1992;267: 17321-17326.